50 results about "Antineoplastic Immunotherapeutic" patented technology

The present invention relates to the field of cancer immunotherapy. Specifically, the present invention relates to the effect of an intestinal-specific strain Anaerostipes caccae ibiome007 on anti-tumor immunity, and provides a method for improving the tumor immunotherapy response rate of patients.

The invention belongs to the technical field of biological medicines, and particularly relates to application of bleomycin or bleomycin analogues in preparation of an immunopotentiator. The invention also provides a pharmaceutical composition and application of the pharmaceutical composition in preparation of drugs for treating and / or preventing cancers. The pharmaceutical composition comprises bleomycin, bleomycin analogues or a combination thereof and an anti-tumor immunotherapeutic agent.

The invention discloses an effect of an Intestinia butyriproducens bacterium in anti-tumor immunotherapy, and finds that colonization of the Intestinia butyriproducens bacterium in intestinal tracts can inhibit growth of CT26 mouse subcutaneous transplanted tumors with poor response to the tumor immunotherapy, meanwhile, growth of human colorectal cancer cells is remarkably inhibited, and apoptosis of tumor cells is promoted for the first time. The application of the Intestinia butyriproducens bacterium in the anti-tumor immunotherapy has the advantages that the effect of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy is achieved, and the application of the intestinia butyriproducens bacterium in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy in the anti-tumor immunotherapy is achieved. Meanwhile, after colonization of the strain and combined administration of PD-1 monoclonal antibodies, the proportion of CD8 + T cells in mouse tumor infiltration lymphocytes is increased, the proportion of depleted PD-1 + CD8 + T cells is reduced, and the proportion of CD8 + T cells releasing functional cell factors interferon gamma and granzyme B is also increased, which shows that after colonization of the strain, the curative effect of tumor immunotherapy can be enhanced, and the tumor immunotherapy effect can be enhanced. The immunoregulation capability and the great clinical application value are realized.

The invention is applicable to the technical field of biomedicine, and provides a preparation method and application of a multifunctional nano composite material. The material has good biocompatibility and can be used as a safe preparation for tumor treatment; the preparation is simple, green and pollution-free; the application of the quercetin in anti-tumor immunotherapy is expanded; the probe has excellent fluorescence / computed tomography dual-mode imaging performance, and can be used for determining tumor boundaries and realizing accurate treatment guidance; the nano-material has excellent photo-thermal and photo-thermal enhanced catalytic performance, has the advantages of being minimally invasive, efficient, small in toxic and side effect, controllable and the like, and can effectively treat primary, metastatic or recurrent head and neck squamous cell carcinoma by activating immunity; by inducing tumor cells to release 2 '3'-cGAMP and preventing the 2 '3'-cGAMP from being degraded, a cGAS-STING signal channel is efficiently activated, and finally the anti-tumor immune effect is enhanced.

The invention relates to the field of biomedicine, in particular to a gene for reversing CD8 + T cell depletion to enhance an immunotherapy effect and application of the gene. The invention firstly provides a medicine for reversing or improving the depletion state of CD8 + T cells. The medicine comprises an inhibitor for inactivating or inhibiting UBASH3A gene expression in the CD8 + T cells and / or an inhibitor for reducing the activity of a signal inhibition factor 2. The invention further provides a composition for enhancing the curative effect of anti-PD-1 / PD-L1 immunotherapy, a kit for predicting the effect of anti-T-cell anti-tumor immunotherapy and the like. The invention provides a new tumor immunotherapy target based on the STS2 protein and an application scheme thereof by deeply researching the action mechanism of the STS2 protein in anti-tumor immunotherapy, brings new breakthrough and progress to the field of tumor immunotherapy, and has important scientific significance and clinical application value.

The invention discloses a homologous targeting neutrophil-liposome system and application thereof in treatment of triple negative breast cancer, the homologous targeting neutrophil-liposome system NE-GI-LNPs is developed and verified for the first time, and the homologous targeting neutrophil-liposome system NE-GI-LNPs can effectively inhibit tumor growth through pyroptosis enhanced anti-tumor immunotherapy. The invention provides a new thought and strategy for research and development of triple negative breast cancer treatment drugs.

The preparation method comprises the following steps: preparing FA-PEG-TK-PBLA-OCT and TPEN (at) NT, then carrying out a reaction on the FA-PEG-TK-PBLA-OCT and the TPEN (at) NT, and inducing TPEN (at) NT encapsulation and micelle formation, so as to prepare STCNs. The STCNs have dual functions of enabling cells to generate endogenous copper death and enhancing antitumor immunotherapy benefits, have good effects on various solid tumor cell strains and PDX animal models, and have relatively high clinical application values.

The invention discloses a temperature-sensitive gel preparation containing a glutaminase inhibitor as well as a preparation method and application of the temperature-sensitive gel preparation, and belongs to the technical field of biological medicines. The temperature-sensitive gel preparation comprises outer-layer gel and inner-layer gel, the inner-layer gel is coated with the outer-layer gel, the outer-layer gel accounts for 40-75% of the total mass of the temperature-sensitive gel preparation, and the inner-layer gel accounts for 25-60% of the total mass of the temperature-sensitive gel preparation; the outer-layer gel is prepared from the following raw materials: an outer-layer gel matrix, a glutaminase inhibitor, a photosensitizer and a stabilizer; the raw materials of the inner-layer gel comprise an inner-layer gel matrix and an immune checkpoint inhibitor. According to the temperature-sensitive gel preparation, through photo-thermal control, the glutaminase inhibitor is firstly released to relieve the immunosuppression state, then the immune checkpoint inhibitor is released to kill tumors, and the glutaminase inhibitor and the immune checkpoint inhibitor act synergistically, so that efficient anti-tumor immunotherapy is achieved.

The invention discloses application of a nutritional agent for removing BCAA in preparation of a medicine, belongs to the technical field of biological medicine, and provides application of the nutritional agent for removing BCAA in preparation of the medicine, and the medicine is a medicine for enhancing tumor immunity and resisting PD-L1. The invention further provides application of the nutritional agent for removing BCAA in preparation of tumor immunotherapy drugs. The invention finds that the nutritional preparation without BCAA can improve the anti-PD-1 / PD-L1 tumor immunotherapy effect by reducing the expression of PD-L1 protein. Therefore, the deletion of BCAA is an effective target for down-regulating PD-L1 expression and improving the curative effect of anti-PD-1 / PD-L1 therapy. The biological function of the BCAA branched chain amino acid is widened, and a new target is provided for tumor immunotherapy and drug development.

The invention belongs to the field of PD-L1 / PD-1 monoclonal antibody tumor immunotherapy, and aims to provide a new research and development direction of PD-L1 / PD-1 monoclonal antibody tumor immunodetection or immunotherapy adjuvant drugs and a new drug combination mode. Experimental results of the invention verify that the invention discloses an application of a reagent for detecting the expression quantity of USP51 in preparation of a detection kit for preparing a PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drug, and discloses an application of a combination of a USP51 inhibitor and a PD-L1 / PD-1 monoclonal antibody drug in preparation of a drug for treating melanoma. The invention discloses an application of a combination of a CD200 inhibitor and a PD-L1 / PD-1 monoclonal antibody in preparation of a drug for treating melanoma, and further discloses an application of a combination of liposome-coated bleomycin and a PD-L1 / PD-1 monoclonal antibody in preparation of a drug for treating melanoma, so that the adverse reaction of bleomycin can be reduced.

The application relates to the technical field of tumor drugs, in particular to application of METTL5 as a tumor immunotherapy targeting site. The base sequence of the METTL5 is shown in SEQ ID No. 1; wherein the METTL5 is a brand-new RNAm6A methyltransferase, is closely related to ribosome translation function, and can regulate the translation of a tumor immune key regulator IL-27; therefore, the METTL5 is used as the tumor immunotherapy targeting site, the expression of the METTL5 related genes or coding proteins is inhibited through targeting, the body anti-tumor immunity can be effectively stimulated, the METTL5 becomes the targeting site capable of enhancing the response rate of tumor immunotherapy, and the METTL5 used as the tumor treatment target point has a wide application prospect in the anti-tumor immunotherapy.

The invention belongs to the technical field of biological medicines, and particularly relates to application of an antiviral drug acyclovir in preparation of a tumor immunotherapy drug. According to the invention, acyclovir is utilized to induce macrophages to become an M1 phenotype, the phagocytic function and the antigen presentation capability of the macrophages are enhanced, and the maturation of dendritic cells is promoted, so that the anti-tumor effect is realized. In an effective concentration which is non-toxic to a macrophage line RAW264.7, acyclovir significantly promotes phenotype transformation of macrophages to M1, and significantly enhances the cell phagocytic ability and antigen presentation ability of the macrophages. Meanwhile, the acyclovir in an effective concentration can also remarkably promote maturation of bone marrow-derived dendritic cells, so that new application of the acyclovir in the field of tumor immunotherapy is found. According to the method, the application range of acyclovir and immune cell immunotherapy is expanded, and a new feasible clinical treatment scheme is provided for anti-tumor immunotherapy.

The invention relates to a bionic intelligent microneedle tumor vaccine as well as a preparation method and application thereof. According to the vaccine, coaxial electrostatic spraying is utilized to construct a drug-loaded microsphere with a core-shell structure, the drug-loaded microsphere is coated with cancer cell-derived membrane protein, and then the drug-loaded microsphere is fixed at the needle point part of a soluble microneedle in a centrifugal manner, so that local drug delivery of crossing a cuticle layer and accurately delivering the drug-loaded microsphere to a corium layer is realized. The microsphere can load demethylated drugs DAC and TAM at the same time, and realizes responsive controlled release in a tumor microenvironment. A plurality of tumor-associated antigens and apoptosis-associated injury-associated molecular patterns carried by the cancer cell membrane protein can promote the maturation of dendritic cells and activate the specific T cell mediated anti-tumor immune response. In conclusion, the microneedle vaccine system integrates multiple functions of precise delivery, controllable release, chemical kinetics treatment, epigenetic regulation, immune activation and the like, the anti-tumor immunotherapy effect can be effectively enhanced, and a new strategy is provided for tumor immunotherapy.

The invention belongs to the technical field of protein polypeptides, and particularly discloses a CD93 affinity peptide and application thereof in preparation of antitumor drugs or detection reagents. The polypeptide with a CD93 protein affinity effect is obtained through repeated screening and optimization, and an affinity blocking activity experiment proves that the CD93 affinity peptide can affine an extracellular IgV-like structural domain of the CD93 protein and block the interaction of CD93 / IGFBP7 protein. An HUVECs cell in-vitro migration experiment and a tube formation experiment verify that the CD93 affinity peptide can inhibit migration of HUVECs cells and tube formation, promote normalization of tumor vascular functions and further inhibit growth of tumors, and has no obvious toxic or side effect. The CD93 affinity peptide provided by the invention can be used for preparing anti-tumor drugs (including anti-tumor immunotherapy drugs) or detection reagents taking CD93 as a target spot, has a better medical application prospect, and provides a new choice for tumor immunotherapy.

The invention discloses a bionic intestinal bacterium and a preparation method and application thereof, and the bionic intestinal bacterium comprises a bionic intestinal bacterium shell and an intestinal bacterium metabolite entrapped in the bionic intestinal bacterium shell; the bionic intestinal bacterial shell comprises: an intestinal bacterial sourced outer membrane vesicle; the intestinal bacterial metabolite comprises one or more of short-chain fatty acid, trimethylamine oxide, inosine and indole-3-formaldehyde. According to the bionic intestinal bacteria disclosed by the invention, the immune regulation function of the intestinal bacteria is reserved, a tumor immunosuppression microenvironment can be effectively regulated into an immune activation microenvironment, the anti-tumor immunotherapy effect is improved, and the risk of direct administration of intestinal flora can be reduced. Besides, the preparation method of the bionic intestinal bacteria is simple, and the bionic intestinal bacteria have good biological safety and potential application prospects in the aspects of tumor treatment and industrial popularization.

The present invention belongs to the field of PD-L1 / PD-1 monoclonal antibody tumor immunotherapy. The purpose of the present invention is to provide a new research and development direction for PD-L1 / PD-1 monoclonal antibody tumor immunotherapy detection or immunotherapy adjuvant drugs, and to develop a new mode of combined medication. Specifically, the present invention provides the use of MTA3 in the preparation of a detection kit for treating PD-L1 / PD-1 monoclonal antibody tumor immunotherapy drugs and the use of MTA3 in combination with PD-L1 / PD-1 monoclonal antibody drugs in the preparation of tumor immunotherapy drugs, wherein the tumor is a solid tumor, and further the solid tumor is melanoma.

The invention belongs to the field of biological medicine, and particularly relates to novel application of a functional regulator of xylosyltransferase 1 (XYLT1) in preparation of drugs for resisting human immunodeficiency virus (HIV) infection and / or resisting tumor immunotherapy. In-vitro experiments prove that up-regulation of expression or activity of XYLT1 can inhibit HIV virus replication (such as reduction of p24 antigen and virus infectivity) and enhance the curative effect of a broad-spectrum neutralizing antibody (such as 3BNC117); meanwhile, the XYLT1 can mediate the degradation of PD-L1 protein, relieve the inhibition on T cells and enhance the anti-tumor killing activity of CD8T cells. The invention provides a new target spot and a combined treatment strategy for immunotherapy of viral diseases and tumors.

This invention discloses an immune cell with enhanced anti-tumor effect, its preparation method, and its application. Experiments using this invention show that... SERTAD1 CD8 gene overexpression + T cells can enhance their function in anti-tumor immunotherapy. SERTAD1 Gene overexpression can downregulate CD8 + The expression of immune checkpoint molecules on T cells upregulates the expression of mRNAs of tumor-killing cytokines. In the MC38-OVA subcutaneous tumor model, Naïve CD8 cells were extracted from OT-I mice. + T cells were infected with a virus to overexpress SERTAD1, followed by adoptive transfer to mice. The results showed that SERTAD1 overexpression enhanced CD8 expression. + T cells kill MC38-OVA cells, inhibit the growth of MC38-OVA tumor cells, and overexpress SERTAD1 CD8. + The tumor volume and weight in the T-cell adoptive group were significantly smaller than those in the control group.

The invention discloses a combined treatment strategy of in-vivo in-situ CAR (Chimeric Antigen Receptor) immunotherapy and a cancer vaccine based on circular RNA (Ribonucleic Acid), which is the first novel tumor immunotherapy which combines an in-vivo in-situ CAR-T / M technology based on circular RNA and a circular RNA cancer vaccine technology, and the technology can be used for rapidly and efficiently generating CAR-T / M cells in vivo; and under the clamping action of a corresponding circular RNA cancer vaccine, a synergistically enhanced anti-tumor immunotherapy effect is further generated. Besides, the specific non-complementary region of the I-type intron from tetrahymena is split, and the in-vitro efficient cyclization of RNA can be realized through the self-splicing of the I-type intron under the conditions of no homologous arm and no additional GTP catalysis.

The invention discloses a chiral iridium complex nano assembly as well as a preparation method and application thereof. The chiral iridium complex nano assembly disclosed by the invention is obtained by carrying out ultrasonic treatment, dialysis and filtration on delta-IrBMS8-mPEG or lambda-IrBMS8-mPEG. The chiral iridium complex nano assembly disclosed by the invention can induce chirality-dependent ferroptosis in a photodynamic therapy (PDT) process and cooperate with blocking of immune checkpoints, so that an anti-tumor immune process is effectively activated, and an efficient synergistic treatment effect is achieved. The preparation method disclosed by the invention is simple and controllable in process, excellent in biological safety and suitable for anti-tumor immunotherapy.

The invention provides a switch element capable of realizing specific response and a lysosomal targeting chimera containing the response switch, which are verified to be capable of specifically degrading target protein contained in tumor cells only in a tumor microenvironment without influencing functions of normal cells of an organism, are simple and convenient in preparation steps, can be used for preparing immune checkpoint blocking drugs, and can be used for preparing immune checkpoint blocking drugs. The tumor treatment effect is improved, the transformation problem and the problem of tumor toxicity in target removal in the prior art are solved, and efficient and safe anti-tumor immunotherapy can be achieved.

The invention discloses an application of a fusobacterium specific antibacterial peptide in preparation of a medicine for improving the anti-tumor immunotherapy effect of a PD-1 antibody. It is found that the fusobacterium specific antibacterial peptide combined with the PD-1 antibody has a remarkable tumor growth inhibition effect. According to the invention, the application range of the fusobacterium specific antibacterial peptide is expanded, and the fusobacterium specific antibacterial peptide has important significance for developing a novel anti-tumor pharmaceutical composition and establishing a novel efficient immunotherapy method.

The invention discloses an application of alpinetin in preparation of a CD8 < + > memory T cell accelerator, a cellular immune drug and an anti-tumor immunotherapy drug. Specifically, the alpinetin can promote the formation of Tscm and / or Tcm cells in CD8 + memory T cells. The alpinetin can promote expression and secretion of IFN-gamma of CD8 < + > memory T cells. The anti-tumor immunotherapy drug is a long-acting anti-tumor drug. According to the alpinetin, by increasing formation of Tscm and / or Tcm cells, expression and secretion of IFN-gamma of CD8 + memory T cells are promoted, the immune response function of the T cells is improved, beneficial support is provided for further exerting the clinical drug effect of the alpinetin, and the alpinetin can be used for preparing a CD8 + memory T cell accelerant, a cellular immune drug and an anti-tumor immunotherapy drug.

An embodiment of the present invention relates to: a vaccine nanoparticle comprising an assembly of cell-penetrating peptides (CPPs) conjugated with deoxycholic acid (DOCA); a method for preparing same; and a vaccine composition for preventing or treating cancer, comprising same. The effects of migration, maturation, and antigen presentation through MHC I in dendritic cells, as well as antigen-specific T cell immune responses through the nanoparticle of the present invention were evaluated in vitro and in vivo. An improved effect was also confirmed through repolarization of tumor-associated macrophages. Additionally, the effect of combination therapy with an immune checkpoint inhibitor was confirmed in a tumor-bearing animal model. The nanoparticle of the present invention induces antigen-specific immunity and macrophage repolarization, thereby improving anti-tumor immunotherapy, and thus can be applied as an mRNA cancer vaccine.

Provided is an in-vivo in-situ CAR immunotherapy and cancer vaccine combined therapy strategy based on circular RNA, which is a novel tumor immunotherapy that combines the cyclic RNA-based in-vivo in-situ CAR-T / M technology and the circular RNA cancer vaccine technology. This novel tumor immunotherapy enables rapid and efficient generation of CAR-T / M cells in vivo and further produces an enhanced collaborative anti-tumor immunotherapy effect with the synergistic action of the corresponding circular RNA cancer vaccine. In addition, a specific non-complementary region of an I-type intron from tetrahymena is split, and thus in-vitro efficient RNA cyclization can be achieved by means of self-splicing of the I-type intron without requiring homologous arms or additional GTP catalysis.

The invention relates to the field of oncolytic virus tumor immunotherapy, in particular to application of oncolytic virus loaded hydrogel to preparation of drugs or preparations for controlling tumor postoperative recurrence. The invention discloses a preparation prepared by wrapping an oncolytic virus with hydrogel prepared from self-assembled polypeptide, which can induce an I-type interferon pathway, activate innate immunity and adaptive immunity and generate anti-tumor immune memory during in-situ continuous release in an operation so as to control postoperative recurrence of tumors and prolong survival. In addition, the invention also discovers that different types of oncolytic viruses wrapped by hydrogel have the same effect of controlling postoperative recurrence of tumors. Therefore, the invention provides a new normal form for continuous anti-tumor immunotherapy.

The invention relates to the technical field of biological medicines, and particularly discloses an mRNA delivery system for targeting dendritic cells as well as a preparation method and application of the mRNA delivery system. The mRNA delivery system is prepared by packaging tumor antigen mRNA into nano-lipid particles (LNP) and coupling the LNP with a specific antibody, and the mRNA delivery system remarkably improves the accuracy and effectiveness of immunotherapy through a'protection-targeting-activation 'triple mechanism, thereby providing technical support for realizing safer and more efficient anti-tumor immunotherapy clinically. On the basis, the invention further provides a vaccine for treating melanoma, and the vaccine has the effects of obviously promoting activation and maturation of DC cells, activating T cells in lymph nodes of a tested body in a tumor microenvironment, obviously improving the expression quantity of melanoma antigen mRNA in the spleen and the like. The goals of inhibiting the growth of melanoma and prolonging the survival time are achieved. The invention is applicable to the field of preparation of tumor vaccines.

The invention discloses an immune cell with an enhanced anti-tumor effect and a preparation method and application of the immune cell, and experiments show that the CD8 + T cell overexpressed by an SERTAD1 gene can enhance the anti-tumor immunotherapy function of the CD8 + T cell. The SERTAD1 gene overexpression can down-regulate expression of immune checkpoint molecules of CD8 + T cells and up-regulate expression of mRNA of cytokines related to tumor killing, in an MC38-OVA subcutaneous tumor model, Nave CD8 + T cells are extracted from an OT-I mouse to over-express SERTAD1 through virus infection, then in-vivo adoptive operation is performed on the mouse, and it is found that the SERTAD1 overexpression can enhance killing of the CD8 + T cells to the MC38-OVA cells, and the SERTAD1 gene overexpression can be used for inhibiting tumor killing of the MC38-OVA cells. The growth of MC38-OVA tumor cells is inhibited, and the tumor volume and weight of an over-expressed SERTAD1 CD8 + T cell adoptive group are obviously smaller than those of a control group.

The invention discloses preparation and application of a Pl3K mutated tumor cell lysate. A preparation method comprises the following steps: constructing a recombinant vector for expressing an amino acid sequence as shown in SEQ ID No.1; transfecting tumor cells with the recombinant vector to obtain a cell line for expressing Pl3K mutant protein; and culturing the cell line expressing the Pl3K mutant protein, collecting the cells, and cracking to obtain the tumor cell lysate. The tumor cell lysate can be applied to antitumor drugs and T lymphocyte immune activation inhibitors. According to the invention, the PI3K mutant is obtained through proper point mutation, the PI3K mutant can effectively inhibit the activation capability of TCL on T lymphocytes, toxic and side effects caused by excessive activation are avoided, a new adoptive cell immunotherapy method based on TCL component optimization is successfully established, and a new thought and strategy are provided for the field of anti-tumor immunotherapy.